Aducanumab
Aducanumab was an amyloid antibody whose US Alzheimer’s indication was later withdrawn. It is historical context, not a current option.
Overview
ENGAGE did not meet its primary endpoint as designed. The product is listed so a past approval is not confused with present availability.
Amyloid-beta–directed antibody. The US Alzheimer’s indication was withdrawn in 2024.
1.Aducanumab binds its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Aducanumab" OR ABSTRACT:"Aducanumab" OR TITLE:"Aduhelm" OR ABSTRACT:"Aduhelm") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Aducanumab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentLecanemab
Shares Anti-amyloid antibodies, Biogen, Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TrialEXPEDITION 3
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentRemternetug
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentDonanemab
Shares Anti-amyloid antibodies, Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TrialCLARITY AD
Shares Biogen, Alzheimer’s disease and the tag dementia-atlas.
- IdeaBlood test before PET or lumbar puncture
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- PersonAlois Alzheimer
Shares Alzheimer’s disease and the tag dementia-atlas.
- TreatmentBrexpiprazole
Shares Alzheimer’s disease and the tag dementia-atlas.